Organism: Homo sapiens
Gene: 38983_at
Selected probe(set): 202001_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38983_at (202001_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):2.6137333
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.3851318
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS5)
	CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.160676
Number of Samples:2 / 2

Experimental	expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.
Control	expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

Relative Expression (log2-ratio):2.1471596
Number of Samples:2 / 2

Experimental	T-cell activation study 4
	T-cell samples antiCD3 activated for 30hrs.
Control	normal resting T-cell sample
	T cells resting for 30h.

Relative Expression (log2-ratio):2.0811758
Number of Samples:3 / 3

Experimental	glioma study 17 (glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):-2.0265255
Number of Samples:2 / 4

Experimental	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.
Control	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

Relative Expression (log2-ratio):1.9443159
Number of Samples:8 / 22

Experimental	septic shock study 3 (D2; non-survivor)
	Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control	normal blood sample
	Blood samples from healthy subjects.

Relative Expression (log2-ratio):-1.9275227
Number of Samples:2 / 2

Experimental	expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control	expO ovary cancer study 1 (dysgerminoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

Relative Expression (log2-ratio):1.9226074
Number of Samples:17 / 22

Experimental	septic shock study 3 (D1; non-survivor)
	Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control	normal blood sample
	Blood samples from healthy subjects.

Relative Expression (log2-ratio):-1.9204779
Number of Samples:2 / 7

Experimental	expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control	expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary.